A total of 692 previously untreated melanoma patients were randomized (T-VEC/pembrolizumab: 346, placebo/pembrolizumab: 346); 6.9% had stage IVM1c disease, 32.7% had high LDH levels, and 64.9% had PD-L1+ status. This evidence concerns the gene CD274 and melanoma.